
Reviva Pharmaceuticals (RVPH) Stock Forecast & Price Target
Reviva Pharmaceuticals (RVPH) Analyst Ratings
Bulls say
Reviva Pharma is a late-stage pharmaceutical company with a promising pipeline and innovative technology platform that could potentially lead to new medicines for various diseases. Key things to monitor include clinical progress for the company's lead asset, brilaroxazine, potential regulatory interactions, and financing activity. The company is currently rated as a Buy with a price target of $2 per share, based on a discounted cash flow (DCF) valuation and other key assumptions. However, there are risks involved, including potential delays in development and approval, potential negative trial results, and potential dilution.
Bears say
Reviva Pharma is a development-stage pharmaceutical company with a limited product pipeline and significant risk factors, such as clinical, regulatory, financial, legal, and intellectual property risks. The company's lead drug candidate, brilaroxazine, has demonstrated potential benefits for the treatment of multiple psychiatric and inflammatory diseases, but its success is not guaranteed given its early-stage development and competition in these markets. Furthermore, the company will need to raise additional capital, likely through equity financing, which could result in share dilution for current shareholders. Combined with the current negative sentiment among investors, we believe that Reviva Pharma's stock may face significant challenges in the near term.
This aggregate rating is based on analysts' research of Reviva Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Reviva Pharmaceuticals (RVPH) Analyst Forecast & Price Prediction
Start investing in Reviva Pharmaceuticals (RVPH)
Order type
Buy in
Order amount
Est. shares
0 shares